KCM
NBSE

Kennedy Capital Management’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Kennedy Capital Management’s Portfolio NBSE Stock Details NBSE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-323
Closed -$1.08M – 764
2014
Q4 		$1.08M Buy
323
+6
+2% +$18.4K 0.02% 652
2014
Q3 		$919K Buy
317
+4
+1% +$13.2K 0.02% 665
2014
Q2 		$1.19M Buy
+313
New +$1.18M 0.02% 635

Other funds holding NBSE

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TI
Turner Investments Berwyn, Pennsylvania $134K AUM 49.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Kennedy Capital Management's NBSE Position: Q1 2015 in Review

Kennedy Capital Management sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q1 2015, closing a stake of 323 shares — an estimated $1.08M sold.

Kennedy Capital Management first reported a position in NBSE in Q2 2014 and held it in 3 quarters. The position peaked at $1.19M in Q2 2014. 64 funds tracked by Wall St. Rank hold NBSE as of Q1 2015.

  • Kennedy Capital Management reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q1 2015 after selling out during the quarter.
  • Kennedy Capital Management sold 323 NeuBase Therapeutics, Inc. Common Stock shares in Q1 2015, an estimated $1.08M.
  • Kennedy Capital Management first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q2 2014 and held it in 3 quarters.
  • Kennedy Capital Management's NeuBase Therapeutics, Inc. Common Stock position peaked at $1.19M in Q2 2014.
  • 64 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q1 2015.

Based on Kennedy Capital Management's 13F filing for Q1 2015, filed 7 May 2015.